Marion Merrell Dow's Cardizem Injectable approved
Executive Summary
Calcium channel blocker will be launched before the end of November. Cardizem Injectable (diltiazem hydrochloride) is approved for atrial fibrillation or atrial flutter and paroxysmal supraventricular tachycardia. The contraindications and warnings are generally similar to those associated with Cardizem tablets; there are additional contraindications for Cardizem Injectable in patients with an accessory bypass tract, in patients who recently received intravenous beta blockers, and for patients with ventricular tachycardia. The product is approved in 25 mg/5 ml and 50 mg/10 ml doses....